文献速递泌尿与男性生殖病理

嗜酸性肾肿瘤最新进展:新见、确证与要点

Recent developments in eosinophilic renal neoplasms: what's new, true and important?
PubMed 文献 · Histopathology · 2026-01-01

本文综述了低级别嗜酸性肾肿瘤、嗜酸性空泡状肿瘤、FLCN突变肿瘤、SDH缺陷性肾细胞癌、上皮样血管平滑肌脂肪瘤/上皮样PEComa、嗜酸性实性和囊性肾细胞癌、ALK重排RCC、FH缺陷性RCC、反向极性乳头状肾肿瘤、管状囊性RCC及甲状腺样滤泡性肾癌等嗜酸性肾实体肿瘤的最新进展。强调病理学家在鉴别诊断中应纳入这些少见实体,常规形态学辅以选择性免疫组化是诊断关键。

要点

  • 嗜酸性肾肿瘤鉴别诊断需纳入LOT、EVT、ESC RCC等少见实体。
  • 常规形态学结合选择性免疫组化是诊断嗜酸性肾肿瘤的关键。
  • 近年对嗜酸性肾肿瘤的临床、病理、免疫组化、分子及预后认识不断更新。

核心结论

  • 病理学家需在嗜酸性肾肿瘤鉴别中考虑少见实体以正确诊断并惠及患者。
  • 常规形态学辅以适当选择性免疫组化是诊断嗜酸性肾肿瘤的关键。

研究设计与样本

  • 综述,聚焦多种嗜酸性肾实体肿瘤的最新进展,不涵盖常见嗜酸性肾肿瘤如透明细胞RCC、乳头状RCC、嫌色细胞RCC、TFE3重排RCC和TFEB改变RCC。

主要发现

  • 综述更新了LOT、EVT、FLCN突变肿瘤、SDH缺陷性RCC、eAML/ePEComa、ESC RCC、ALK重排RCC、FH缺陷性RCC、PRNRP、TC-RCC和TLFCK等实体的临床、病理、免疫组化、分子、流行病学和预后方面的新知识。

临床怎么用

  • 在嗜酸性肾肿瘤鉴别诊断中应纳入本综述所述少见实体。
  • 诊断时强调常规形态学并辅以适当的选择性免疫组化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We focus in this review on the latest developments on several eosinophilic renal entities, aiming to provide an update on this topic that was previously addressed by the Genitourinary Pathology Society in their consensus papers on existing renal entities, and on novel, emerging, and provisional renal entities, and in the World Health Organization 2022 Classification of Renal Cell Tumours (5th Edition). The scope of this review includes an update on more recently described eosinophilic renal entities, including low-grade oncocytic renal tumour (LOT), eosinophilic vacuolated tumour (EVT), folliculin (FLCN) mutated tumour, succinate dehydrogenase (SDH)-deficient renal cell carcinoma, epithelioid angiomyolipoma/epithelioid PEComa (eAML/ePEComa), eosinophilic solid and cystic renal cell carcinoma (ESC RCC), anaplastic lymphoma kinase (ALK)-rearranged RCC, fumarate hydratase (FH)-deficient RCC, papillary renal neoplasm of reversed polarity (PRNRP), tubulocystic RCC (TC-RCC), and thyroid-like follicular carcinoma of kidney (TLFCK). These renal entities fall within the spectrum of eosinophilic renal tumours, in addition to the more common ones with eosinophilic features that will not be covered in this review, such as clear cell renal RCC, papillary RCC, chromophobe RCC, TFE3 rearranged RCC, and TFEB-altered RCC. Pathologists need to consider these less common renal entities in the differential of any eosinophilic renal tumour to be able to diagnose them for the benefit of their patients. The recent developments and acquired knowledge on newer renal entities with eosinophilic cytoplasm opened insights into the clinical, pathological, immunohistochemical, molecular, epidemiological aspects, and the prognosis of these entities. We emphasize the role of routine morphology, aided by appropriate and select immunohistochemistry, as essential keys for diagnosing eosinophilic renal tumours.

来源:Histopathology,查看原文。版权归原作者所有。

引用

  1. Trpkov K, Siadat F, Saleeb R, et al. Recent developments in eosinophilic renal neoplasms: what's new, true and important? Histopathology. 2026. PMID: 41384711. doi:10.1111/his.70001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。